Was the exacerbation of PTSD symptoms after high doses of venlafaxine due to the noradrenergic mechanism? A case report

Rocha, Felipe Filardi da; Corrêa, Humberto

doi:10.1590/s1516-44462007000100030

Cited by 2 publications

(1 citation statement)

References 3 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Different from the SSRIs, prazosin acts primarily in the noradrenergic system. Noradrenergic stimulation of limbic structures, as hippocampus and amygdale, by the locus coeruleus maintains alertness, attention and consolidates frightening experiences memories, necessary for the PTSD development [8][9][10][11][12] .…”

Section: Introductionmentioning

confidence: 99%

Prazosina de liberação lenta para pacientes com transtorno do estresse pós-traumático resistentes aos ISRS

Pagotto¹,

Berger²,

Mendlowicz³

et al. 2012

Rev. psiquiatr. clín.

View full text Add to dashboard Cite

Background: Prazosin is an antagonist of alpha-1 adrenergic receptor used to treat PTSD-related nightmares and insomnia. Although evidence suggests that it is also effective in the treatment of general symptoms of PTSD, its short half-life (2-3 hours) may limit its therapeutic effects. Objective: To describe four cases of patients with PTSD resistant to selective serotonin reuptake inhibitors (SSRIs) or selective serotonin/noradrenaline reuptake inhibitor (SNRIs) therapy (conventional therapy) treated with slow-release prazosin presentation. Methods: Four patients with severe PTSD resistant to conventional therapy received slow-release prazosin (half-life of 10.8 hours) added to their prescription for at least three months. PTSD symptoms were evaluated by the PCL-C, together with nightmares and insomnia items of CAPS, at baseline and at the last observation of each patient. Results: Two patients showed improvement in general symptoms of PTSD (reduction of 35.7% and 11.9% in PCL-C scores), and three showed relief from nightmares and insomnia (CAPS scores). The only patient who received morning and bedtime doses of prazosin showed the greatest improvement in general symptoms of PTSD. Discussion: It is possible that the sustained blockade of noradrenergic activity in the central nervous system provided by slow-release prazosin during the day is necessary to further ameliorate residual PTSD symptoms in patients receiving conventional antidepressant therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Prazosina de liberação lenta para pacientes com transtorno do estresse pós-traumático resistentes aos ISRS

Pagotto¹,

Berger²,

Mendlowicz³

et al. 2012

Rev. psiquiatr. clín.

View full text Add to dashboard Cite

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2007

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Was the exacerbation of PTSD symptoms after high doses of venlafaxine due to the noradrenergic mechanism? A case report

Cited by 2 publications

References 3 publications

Prazosina de liberação lenta para pacientes com transtorno do estresse pós-traumático resistentes aos ISRS

Prazosina de liberação lenta para pacientes com transtorno do estresse pós-traumático resistentes aos ISRS

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About